Patents Examined by Fozia Hamud
  • Patent number: 10844138
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 24, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Patent number: 10815305
    Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 27, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie M. Orengo, Jeanne Allinne, Andrew J. Murphy, George D. Yancopoulos
  • Patent number: 10800841
    Abstract: Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 13, 2020
    Assignee: VITAERIS, INC.
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
  • Patent number: 10793599
    Abstract: The present invention provides MPHOSPH1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: October 6, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Sachiko Yamashita, Tetsuro Hikichi
  • Patent number: 10793629
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 6, 2020
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Patent number: 10787509
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: September 29, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Steven Grant, Martin Orecchia, Chika Akinseye, Laura Hook, Alan Lewis, Tejinder Bhinder
  • Patent number: 10787511
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 29, 2020
    Assignee: VITAERIS INC.
    Inventor: Jeffrey T. L. Smith
  • Patent number: 10774128
    Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: September 15, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
  • Patent number: 10774141
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: September 15, 2020
    Assignee: Suzhou Connect Biopharmaceuticals, Ltd.
    Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
  • Patent number: 10774148
    Abstract: The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 15, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takahiro Kakehi, Akinori Yamada, Yoshimasa Ishida
  • Patent number: 10765724
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: September 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
  • Patent number: 10760049
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 1, 2020
    Assignee: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan Reubinoff
  • Patent number: 10723795
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Patent number: 10695406
    Abstract: Disclosed are compositions and methods for modulating oxidative and/or endoplasmic reticulum (OER) stress. More particularly, the present invention discloses compositions and methods that target OER stress inhibitors to pancreatic cells for treating diseases associated with oxidative and/or OER stress, including metabolic disorders such as diabetes.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 30, 2020
    Assignee: The University of Queensland
    Inventors: Michael McGuckin, Johannes Prins, Sumaira Hasnain
  • Patent number: 10688119
    Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 23, 2020
    Assignee: Aarhus Universitet
    Inventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
  • Patent number: 10683349
    Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 16, 2020
    Assignee: NOVARTIS AG
    Inventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
  • Patent number: 10676514
    Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 9, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yamashita, Tomohisa Watanabe
  • Patent number: 10676522
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 9, 2020
    Assignee: NOVARTIS AG
    Inventors: Sarah Schmidt Grant, Shamsah Kazani, Edward Khokhlovich, Jason Laramie, Robert Martin Strieter, Tricia Ann Thornton-Wells
  • Patent number: 10668150
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 2, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • Patent number: 10662240
    Abstract: A synergistic composition, kit and method for inhibition and/or neutralization of IL-21 mediated activation of human cells including (i) a first agent being an antibody or antibody fragment thereof directed to a first epitope of IL-21, and (ii) a second agent being an antibody or antibody fragment thereof directed to a second epitope of IL-21 is disclosed. The inhibition and/or neutralization of IL-21 mediated activation of human cells is for use in the prophylaxis and/or treatment of disease of immune-related conditions including inflammatory disease, autoimmunity and lymphomas.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: May 26, 2020
    Assignee: MABTECH AB
    Inventors: Niklas Ahlborg, Staffan Paulie